abstract |
The present application relates to pharmaceutical preparations and dosage forms of lysine-specific demethylase-1 (LSD1) inhibitors or pharmaceutically acceptable salts, solvates or hydrates thereof, including methods for their preparation, the pharmaceutical preparations and The dosage form is suitable for use in the treatment of LSD1 mediated diseases, such as cancer. |